Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with sinemet CR

Clinical Neuropharmacology

Volumn 28, Issue 3, 2005, Pages 115-119

  Paija, Outi ^a,b   Laine, Kari ^a,b   Kultalahti, Eeva Riitta ^d   Leinonen, Mika ^d   Huupponen, Risto ^a,b,c   Gordin, Ariel ^d   Reinikainen, Kari ^d  

^a Clinical Research Services   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d ORION CORPORATION   (Finland)

Author keywords

Catechol O methyltransferase inhibition; Controlled release levodopa; Entacapone; Levodopa pharmacokinetics

Indexed keywords

3 O METHYLDOPA; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ANTIPARKINSON AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HEART RATE; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE;

EID: 21544474680     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000166393.33781.87     Document Type: Article

References (33)

1. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002;359: 1589-1598.
2. Widner H. Strategies to modify levodopa treatment. Adv Neurol. 2003;91: 229-236.
3. Yeh KC, August TF, Bush D, et al. Pharmacokinetics and bioavailabiliry of Sinemet CR: a summary of human studies. Neurology. 1989;39(Suppl 2): 25-38.
4. Kaakkola S. Clinical pharmacology, therapeutics and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000;59:1233-1250.
5. Gordin A, Kaakkola S, Teräväinen H. Position of COMT inhibition in the treatment of Parkinson's disease. Adv Neurol. 2003;91:237-250.
6. Nissinen E, Linden IB, Schultz E, et al. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol. 1992;346:262-266.
7. Colosimo C. The rise and fall of tolcapone. JNeural. 1999;246:880-882.
8. Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase after oral and intravenous administration of entacapone. Eur J Clin Pharmacol. 1994;46:151-157.
9. Heikkinen H, Saraheimo M, Antila S, et al. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor in man. A study using a stable isotope technique. Eur J Clin Pharmacol. 2001;56:821-826.
10. Keränen T, Gordin A, Harjola V-P, et al. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol. 1993;16:145-156.
11. Kaakkola S, Teräväinen H, Ahtila S, et al. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology. 1994;44:77-80.
12. Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1994;57:186-189.
13. Myllylä VV, Sotaniemi KA, Illi A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol. 1993;45:419-423.
14. Nutt JG, Woodward WR, Stone CR, et al. Effects of an inhibitor of catechol-O-methyltransferase (COMT) on the pharmacokinetics and pharmacodynamics of levodopa. Neurology. 1994;44:913-919.
15. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjunct to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol. 1996;19:283-296.
16. Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol. 1996;19:222-233.
17. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month's double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry. 1996;60:36-40.
18. Rinne UK, Larsen JP, Siden Å, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology. 1998;51:1309-1314.
19. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa treated Parkinson's disease patients. Ann Neurol. 1997;42:747-755.
20. Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa responses: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105:2-12.
21. Brooks DJ, Sagar H, UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo-controlled, double-blind, six-month study. J Neurol Neurosurg Psychiatry. 2003;74:1071-1079.
22. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa/carbidopa in volunteers. Clin Neuropharmacol. 1995;18:45-57.
23. Kaakkola S, Teräväinen H, Ahtila S, et al. Entacapone in combination with standard or controlled release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol. 1995;2:1-7.
24. Piccini P, Brooks DJ, Korpela K, et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;68:589-594.
25. Stocchi F, Barbato L, Nordera G, et al. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. J Neural Transm. 2004;111:173-180.
26. Wikberg T. Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal. 1991;9:167-176.
27. Rowland M, Tozer TN. Clinical pharmacokinetics. Concepts and applications. 3rd ed. Philadelphia: Lippincott, William & Wilkins; 1995:101-102.
28. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1984;i:345-349.
29. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain. 1984;107:487-509.
30. Fabbrini G, Juncos J, Mouradian M, et al. Levodopa pharmacokinetics and motor fluctuations in Parkinson's disease. Ann Neurol. 1987;2:370-376.
31. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci. 2000;23(Suppl 1): S109-S115.
32. Olanow CW, Schapira HV, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 2000;23(Suppl 1): S117-S126.
33. Heikkinen H, Varhe A, Laine T, et al. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol. 2002;54:363-371.